Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST)

Figures

• 

  Figure 1. Time to all-cause death for pooled TRUST, ECOST, and IN-TIME patients. The shaded areas indicate the 95% CIs. The numbers below panel are patients at risk. The 1.9% reduction in the absolute risk of death in the HM group was statistically significant (95% CI: 0.1–3.8%; P = 0.037). Abbreviations: HM, Home Monitoring; ECOST/IN-TIME/TRUST as in Table 1.

• 

  Figure 2. Forest plot of the absolute risk differences (in %) for all endpoints at 12 months. A negative value (reduction) is in favour of HM. Abbreviations: CI, confidence interval; CV, cardiovascular; hosp, hospitalization; WHF, worsening heart failure; ECOST/IN-TIME/TRUST as in Table 1.

• 

  Figure 3. Time to occurrence of composite endpoints for pooled ECOST and IN-TIME patients. Upper panel: Composite of all-cause death and a CV hospitalization, excluding device related or procedure-related hospitalizations. The 4.1% absolute risk reduction in the HM group was not statistically significant (P = 0.13). Lower panel: Composite of all-cause death and a hospitalization due to WHF. The 5.6% absolute risk reduction in the HM group was statistically significant (P = 0.007). For confidence intervals, see Figure 2. Abbreviations as in Figures 1 and 2.